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ABSTRACT
Introduction Low high- density lipoprotein (HDL) is widely 
used as a marker of cardiovascular disease risk, although 
this relationship is not causal and is likely mediated 
through associations with other risk factors. Low HDL is 
extremely common in sub- Saharan African populations, 
and this has often been interpreted to indicate that these 
populations will have increased cardiovascular risk. We 
aimed to determine whether the association between HDL 
and other cardiovascular risk factors differed between 
populations in sub- Saharan Africa and the UK.
Methods We compared data from adults living in Uganda 
and Malawi (n=26 216) and in the UK (n=8747). We 
examined unadjusted and adjusted levels of HDL and 
applied the WHO recommended cut- offs for prevalence 
estimates. We used spline and linear regression to assess 
the relationship between HDL and other cardiovascular risk 
factors.
Results HDL was substantially lower in the African 
than in the European studies (geometric mean 0.9–
1.2 mmol/L vs 1.3–1.8 mmol/L), with African prevalence 
of low HDL as high as 77%. Total cholesterol was also 
substantially lower (geometric mean 3.3–3.9 mmol/L vs 
4.6–5.4 mmol/L). In comparison with European studies 
the relationship between HDL and adiposity (body mass 
index, waist to hip ratio) was greatly attenuated in African 
studies and the relationship with non- HDL cholesterol 
reversed: in African studies low HDL was associated with 
lower non- HDL cholesterol. The association between sex 
and HDL was also different; using the WHO sex- specific 
definitions, low HDL was substantially more common 
among women (69%–77%) than men (41%–59%) in 
Uganda/Malawi.
Conclusion The relationship between HDL and sex, 
adiposity and non- HDL cholesterol in sub- Saharan Africa 
is different from European populations. In sub- Saharan 
Africans low HDL is a marker of low overall cholesterol 
and sex differences are markedly attenuated. Therefore 
low HDL in isolation is unlikely to indicate raised 
cardiovascular risk and the WHO sex- based cut- offs are 
inappropriate.
INTRODUCTION
The inverse relationship between high- 
density lipoprotein (HDL) and cardiovascular 
disease (CVD) is well established in European 
and North American populations.1 2 While 
low HDL is strongly associated with CVD 
Key questions
What is already known?
 ► A number of studies have shown a high prevalence 
of low high- density lipoprotein (HDL) in sub- Saharan 
African populations despite low levels of obesity.
 ► In other populations, low HDL is strongly associated 
with higher non- HDL cholesterol, obesity and in-
creased cardiovascular risk, and HDL is substantially 
lower in men than in women.
 ► The relationship between low HDL and cardiovas-
cular risk is not causal and is therefore mediated 
through associations with other causal risk factors.
What are the new findings?
 ► This study demonstrates using data from two sub- 
Saharan African countries and two European studies 
the different associations between HDL and other 
cardiovascular risk factors, with low HDL associated 
with lower non- HDL cholesterol.
 ► Our findings also demonstrate that HDL differenc-
es between men and women documented in many 
populations are markedly reduced in sub- Saharan 
African studies.
What do the new findings imply?
 ► Lower HDL in sub- Saharan African populations is 
part of a pattern of lower overall cholesterol.
 ► Until prospective studies of cardiovascular outcomes 
are available, isolated low HDL in sub- Saharan 
Africans should not be taken to indicate raised car-
diovascular risk.
 ► Current WHO thresholds for low HDL, which differ 
substantially by sex, do not appear appropriate for 
this population.
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risk, Mendelian randomisation and trials of HDL- raising 
agents have demonstrated that HDL is not causally associ-
ated with cardiovascular risk, and therefore the relation-
ship between low HDL and higher cardiovascular risk is 
likely to be driven by other factors associated with low 
HDL, such as increases in non- HDL cholesterol and low- 
density lipoprotein (LDL).3–6 Despite the lack of causal 
association HDL remains a strong predictor of cardiovas-
cular risk that is widely used in cardiovascular risk predic-
tion.3 7 Low HDL in studied populations is associated 
with other cardiovascular risk factors, such as obesity and 
ectopic fat deposition, high non- HDL cholesterol and 
LDL, high triglycerides, and hypertension.8
A number of studies have shown that low HDL is 
common in sub- Saharan African populations.9–15 Low 
HDL is by far the most common dyslipidaemia in sub- 
Saharan Africa.11 This has been interpreted by many as 
an indicator of escalating CVD risk, driven by increasing 
urbanisation, westernisation of diets and increasingly 
sedentary lifestyles.11 14 However, low HDL in these popu-
lations is often much more prevalent than other CVD risk 
predictors, such as obesity and high LDL cholesterol and 
triglycerides.10 12 15 In addition, while low HDL is strongly 
associated with increasing adiposity in European, North 
American, Indian and Chinese populations, sub- Saharan 
African studies have found a high prevalence of low HDL 
even among predominantly thin rural dwellers and in 
those with low body mass index (BMI).9 14 16–23
We aimed to determine whether the relationship 
between HDL and other cardiovascular risk factors differs 
between two populations in sub- Saharan Africa, where 
low HDL is widespread, and a European population.
METHODS
Study design and participants
We assessed the relationship between HDL and cardio-
vascular risk factors in population studies from Malawi 
and Uganda and compared these relationships with 
UK studies. Included studies (with the exception of 
the Exeter Family Study, EFS) were population studies 
(described in the next section), and participants were 
excluded from this analysis if they were aged under 18, 
were HIV- positive, reported pregnancy at the time of data 
collection or had diabetes. Individuals missing sex and 
lipid data were excluded from analysis. After these exclu-
sions, 21 608 participants remained in the Malawian study 
(10 428 rural and 11 180 urban), 4608 in the Ugandan 
cohort, 1459 in the UK family study and 7288 in the 
Exeter 10,000 cohort (EXTEND). A flow chart demon-
strating the effect of these exclusion criteria is shown in 
online supplemental figure 1.
Data collection
Data collection methods for each of the studies have been 
described in detail elsewhere.24–26 All studies were cross 
sectional and collected survey data on sociodemographic 
variables, anthropometric measurements and a fasted 
blood sample.24–26
MEIRU Urban/Rural NCD Survey, Malawi
In Malawi, rural participants were recruited through an 
existing demographic surveillance site and urban partic-
ipants were invited to partake through a full enumera-
tion of Area 25 of the capital city, Lilongwe, as previously 
described.25 All participants were aged ≥18 at recruit-
ment. If participants had not fasted, they were revisited, 
and if they had not fasted on the second occasion a 
random blood sample was collected. Laboratory analysis 
of lipids was undertaken by the Malawi Epidemiology 
and Intervention Research Unit (MEIRU) laboratory 
using enzymatic assays on the Beckman Coulter Chem-
istry Analyser.27 Lipids were measured in all participants 
consenting to a blood sample (24 982 of 31 012 cohort 
participants).
Masaka General Population Cohort, Uganda
In Uganda, all resident individuals aged ≥13 in the study 
area of the General Population Cohort were invited to 
participate in the study, as previously described.24 Lipids 
were measured using enzymatic, colourimetric assays on 
the Cobas Integra 400 analyser.28 Lipid analysis was under-
taken in all adults in the 2011 survey round consenting to 
a blood sample (5856 adult participants).
Exeter 10,000, UK
The EXTEND study was an unselected population cohort 
recruited in the South West of England from the commu-
nity and from primary care settings. Lipids were analysed 
by the Blood Sciences Laboratory of the Royal Devon and 
Exeter NHS Foundation Trust using enzymatic, colouri-
metric assays on the Roche Cobas system.
Exeter Family Study, UK
In the EFS, all resident white women in Exeter without 
diabetes with a singleton pregnancy were invited to the 
study, along with their partners.26 Data were collected 
from mothers after birth (in order to obtain data from 
outside of pregnancy, mean follow- up time was 6 years 
and 5 months after birth). Total cholesterol, HDL 
and triglycerides were directly measured by the Blood 
Sciences Laboratory of the Royal Devon and Exeter NHS 
Foundation Trust using enzymatic, colourimetric assays 
on the Roche Cobas system.
LDL cholesterol in all studies was estimated by modified 
Friedewald formula. Non- HDL cholesterol was calculated 
for all studies by subtracting HDL from total cholesterol.
Statistical analysis
Definitions of dyslipidaemia and obesity
BMI categories, low HDL, high total cholesterol, triglyc-
erides and high blood pressure were defined by the WHO 
cut- offs.29 BMI was defined as underweight if it was <18.5, 
normal from 18.5 to <25, overweight from 25 to <30, and 
obese ≥30. Low HDL was defined as <1.03 mmol/L for 
men and <1.29 mmol/L for women. Total cholesterol was 
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defined as high if it was ≥6.2 mmol/L. High triglycerides 
was defined as ≥1.7 mmol/L. The WHO does not use a 
specific definition of high LDL, but in a recent review of 
dyslipidaemias in sub- Saharan Africa the most commonly 
used diagnostic cut- off was 3.3 mmol/L, which is in 
line with the guidance of the US National Cholesterol 
Education Program.11 High blood pressure was defined 
as systolic blood pressure ≥140 mm Hg and/or diastolic 
≥90 mm Hg or on antihypertensive medication.29
Analysis
Analysis is based on participants with complete lipid data. 
Men and women were analysed separately due to the 
existing evidence of a sex difference in HDL.30 Addition-
ally, rural and urban participants in the Malawian cohort 
were analysed separately as there is evidence of a relation-
ship between location of residence and lipid profile.14 22 
Non- normally distributed variables were log- transformed 
and geometric means and 95% CIs are reported if log- 
transformed variables were normally distributed. Log 
age remained highly skewed, so median and IQR are 
reported. Unadjusted baseline characteristics of men and 
women in each cohort are reported. The geometric mean 
HDL for each cohort, adjusted to the average age and 
BMI and smoking status of the Malawian cohort, is also 
reported, alongside analysis that also adjusted for alcohol 
consumption. The association of HDL with deprivation 
was explored separately in each cohort, as these studies 
used different measures of assessing deprivation. Spline 
regressions with 3 df were plotted to explore the relation-
ships between CVD risk factors in each cohort separately 
for men and women. Where relationships were linear, 
linear regression analysis was conducted and β-coeffi-
cients with 95% CIs are reported. Sensitivity analysis were 
carried out. We conducted identical analyses excluding 
participants using lipid- lowering medication and individ-
uals who consumed alcohol daily.
Software
Statistical analysis was performed and data visualisations 
created using Stata SE V.16.0 and R, using RStudio 
V.1.2.5001.
Patient and public involvement
Patients and/or the public were not involved in the 




The characteristics of the included participants are 
shown in table 1. Participants in the EXTEND study were 
substantially older than other studies, with BMI higher in 
the UK than in African studies. One hundred per cent of 
participants in the Malawian and Ugandan studies were 
black African, while 100% of those in EFS and 98% of 
those in EXTEND were white European. Smoking was 
less common among women in all studies.
Missing data and exclusion criteria
Online supplemental figure 1 shows the effect of study 
inclusion criteria and missing data. Of 42 001 meeting 
the study inclusion criteria (aged over 18, not pregnant, 
HIV- negative and did not have diabetes), 7045 could not 
be included in analysis due to missing data. The charac-
teristics of participants with missing data were similar to 
the included participants (online supplemental table 1).
Low HDL is highly prevalent in sub-Saharan African 
populations
Table 2 shows the lipid levels and the prevalence of dyslip-
idaemia by the WHO definitions for men and women in 
the included studies. Despite low overall prevalence of 
obesity, HDL was consistently lower in all of the groups 
in the African studies than in the UK. Total cholesterol 
was also substantially lower in African studies, with the 
ratio of total cholesterol to HDL broadly similar in men 
from the UK and sub- Saharan Africa, but higher in sub- 
Saharan African women than those from the UK. Low 
HDL was extremely common in African studies, ranging 
from 41% to 77% of participants across studies and sex 
(table 2).29 This is in contrast to the UK studies where 
low HDL was infrequent (10%–17%). In contrast, other 
dyslipidaemias were less common in the African studies, 
with 12%–21% of Malawian study participants and only 
4%–11% of Ugandans having raised LDL, while in the 
UK studies the prevalence of high LDL was 14%–43% 
(table 2). This is despite 15% of men and 6% of women 
in EXTEND using lipid- lowering medication, compared 
with 0%–0.5% in each of the sub- Saharan African studies 
(these data were not available for participants in the EFS). 
Among the sub- Saharan African studies, 5%–15% had 
raised triglycerides by the WHO definitions, compared 
with 5%–28% in the UK studies (table 2).29
Differences in HDL between UK and African studies were not 
explained by known potential confounders
In the analysis adjusted for age, BMI and smoking status, 
estimates were similar, with marked differences in HDL 
between African and UK populations (figure 1; adjusted 
for age only in online supplemental figure 2). While lack 
of comparable measures meant we could not adjust across 
studies to assess the effects of socioeconomic status, this 
was not substantially associated with HDL within indi-
vidual studies—where there were statistically significant 
results, the effect sizes were negligible (online supple-
mental table 2). Self- reported alcohol consumption was 
recorded in Malawi, Uganda and in the EXTEND study, 
and the results were similar with additional adjustment 
for alcohol consumption in these studies (online supple-
mental figure 3).
Sex differences in HDL seen in European populations are 
reduced in sub-Saharan African studies
In the UK studies, HDL was substantially higher in female 
participants (table 2), consistent with the gender- specific 
thresholds used to define low HDL internationally.31 In 
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contrast, in African studies there were only minor differ-
ences in HDL between genders. For example in Malawian 
populations the geometric mean HDL was 1.05 and 1.10 
in men and women, respectively, in the rural site and 1.10 
and 1.15 in the urban site (table 2). This meant that using 
the WHO definitions of low HDL, which specify a higher 
cut- off for women than men, the prevalence of low HDL 
was markedly higher in women than in men in African 
studies. For example in Malawi the prevalence of ‘low’ 
HDL using the WHO criteria was 69%–77% in women 
and 41%–59% in men. In contrast, among the UK studies 
there was a similar prevalence of low HDL between men 
and women using WHO criteria.
The relationship between adiposity and HDL is substantially 
different between European and African studies
In the UK, as expected, a clear inverse relationship 
between BMI and HDL was observed in both men and 
women; in comparison this was near absent in all of the 
African groups (figure 2 for spline regression and online 
supplemental table 3 for linear regression with and 
without adjustment for age, smoking status and alcohol 
consumption). These findings were similar when waist 
to hip ratio is used as a measure of adiposity in place of 
BMI (online supplemental figure 4). In linear regression 
analysis the β-coefficients for the relationship between 
BMI and HDL were significantly lower in the sub- Saharan 
African studies than in the UK in unadjusted analysis 
(β-coefficient (95% CI) among men: −0.034 (−0.037 to 
–0.031) in the UK and −0.007 (−0.009 to −0.005) in sub- 
Saharan Africa; among women: −0.031 (−0.034 to –0.029) 
in the UK and −0.004 (−0.005 to −0.003) in sub- Saharan 
Africa; online supplemental table 3). The results were 
similar when adjusted for age, smoking status and alcohol 
consumption (online supplemental table 3).
In contrast, the relationship between BMI and 
triglycerides was broadly similar across all of the studies 
in both men and women, with triglycerides increasing 
with increasing BMI (figure 3).
The relationships between HDL and other lipids are markedly 
different in UK and African studies
In UK studies there is a strong inverse relationship 
between HDL and non- HDL cholesterol. In marked 
contrast, this relationship reversed in African studies, 
where low HDL is associated with lower non- HDL choles-
terol (figure 4). This was similar for calculated LDL 
(online supplemental figure 5). In linear regression anal-
ysis, the β-coefficients for the relationship were substan-
tially different in unadjusted analysis (β-coefficient 
(95% CI) among men: −0.089 (–0.100 to –0.078) in the 
UK and +0.046 (0.038 to 0.054) in sub- Saharan Africa; 
among women: −0.069 (−0.081 to –0.057) in the UK and 
+0.041 (0.036 to 0.047) in sub- Saharan Africa), and this 
difference remained in adjusted analysis (online supple-
mental table 2). While lower HDL was associated with 
higher triglycerides for all studies, the magnitude of the 
relationship between HDL and triglycerides is far smaller 
in sub- Saharan African participants (figure 5). In linear 
regression analysis, the β-coefficients for the relation-
ship between triglycerides and HDL were substantially 
reduced in the sub- Saharan African studies compared 
with the UK, both in unadjusted analysis (β-coefficient 
(95% CI) among men: −0.243 (–0.259 to –0.227) in the 
UK and −0.075 (−0.085 to −0.064) in sub- Saharan Africa; 
among women: −0.327 (–0.350 to –0.305) in the UK and 
−0.119 (−0.128 to −0.109) in sub- Saharan Africa) and in 
adjusted analysis (online supplemental table 2). These 
Figure 1 Geometric mean high- density lipoprotein (HDL) 
for each cohort, adjusted to the median age (31 years) 
and geometric mean body mass index (23.21 kg/m2) of the 
Malawian cohort. All studies were adjusted for smoking 
status, apart from female participants in the Exeter Family 
Study, for whom smoking data were not available. Figure 2 Spline regression showing HDL at each level of 
BMI for each cohort. BMI, body mass index; EFS, Exeter 
Family Study (UK); EXT, Exeter 10,000 study (UK); HDL, high- 
density lipoprotein.
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results were similar in a sensitivity analysis in which we 
excluded participants who were using lipid- lowering 
medication (online supplemental figures 6–8 and table 
4).
In each of the studies that had blood pressure values 
available, the relationship to HDL was broadly similar, 
with a very modest increase in HDL with higher blood 
pressure (online supplemental figure 9).
DISCUSSION
In these large community studies, HDL was substantially 
lower in sub- Saharan Africa than in the UK, despite the 
markedly lower overall prevalence of obesity and other 
dyslipidaemias. In African cohorts low HDL appears to 
largely reflect lower overall lipids and the association 
between HDL and other risk factors is substantially 
different: in contrast to UK studies, in sub- Saharan 
African participants a low HDL is associated with lower 
non- HDL cholesterol. Given the strong causal relation-
ship between the major components of non- HDL choles-
terol and cardiovascular risk, this suggests that isolated 
low HDL is unlikely to indicate increased cardiovascular 
risk in sub- Saharan African populations.
Comparison with previous research
Our findings of a high prevalence of HDL below the 
WHO thresholds are consistent with previous studies in 
sub- Saharan African populations which suggest this is 
common across sub- Saharan Africa and not confined to 
the East and Southern African populations included in 
this research.9 14 16 22 23 31–34 This appears to be the case 
at different stages of economic development, with half 
of black South Africans reported to have low HDL.33 
Our finding of a weaker relationship between BMI and 
HDL in sub- Saharan African studies in comparison with 
the UK is consistent with studies in other sub- Saharan 
African countries showing that low levels of HDL are 
common among individuals with low BMI,9 16 and studies 
demonstrating lower levels of HDL in rural dwellers 
than urban, despite urban residence usually being asso-
ciated with increased levels of obesity.14 22 23 31 This is also 
constant with recent analysis comparing the relationship 
between lipids and both BMI and waist to hip ratio in 
Figure 3 Spline regression showing triglycerides at each 
level of BMI for each cohort. BMI, body mass index; EFS 
Exeter Family Study (UK); EXT, Exeter 10,000 study (UK).
Figure 4 Spline regression showing HDL at each level of 
non- HDL for each cohort. EFS, Exeter Family Study (UK); 
EXT, Exeter 10,000 sudy (UK); HDL, high- density lipoprotein.
Figure 5 Spline regression showing HDL at each level of 
triglycerides for each cohort. EFS, Exeter Family Study (UK); 
EXT, Exeter 10,000 study (UK); HDL, high- density lipoprotein.
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Malawi compared with the UK, using the same Malawian 
cohort.15
Our findings within people living in Africa are in 
contrast to studies of people of African origin living in 
high- income countries. Black African migrants to high- 
income countries have higher HDL levels than people 
of their ethnic origin in sub- Saharan African, although 
they have higher BMI.31 35 For example, individuals of 
Ghanaian descent who live in European capitals have 
significantly higher HDL concentrations than those who 
live in rural and urban Ghana.31 Similarly, low HDL is less 
common among West African migrants in North America 
than in Africans in Africa.35 A number of studies in 
Europe have shown that people of black African descent 
have similar or more favourable lipid profiles (including 
higher HDL) than Caucasians.36–41
Although novel genetic associations with HDL in sub- 
Saharan Africa have been reported, the very different 
finding in African origin populations living in high- 
income countries suggests that differences in HDL 
levels and associations are of environmental, rather than 
genetic, origin.42 The specific environmental exposures 
that drive these changes are unclear. Potential explana-
tions may include dietary differences; for example, low 
fat intake may result in reduced HDL cholesterol, and 
this dietary pattern is common in sub- Saharan Africa.43 44 
A further potential explanation is the effects of infection 
or inflammation, which have been shown to be associ-
ated with a decrease in HDL.45 It is, however, intriguing 
that this is not substantially influenced by rural or urban 
dwelling and habits. The different association between 
low HDL and other characteristics like sex, BMI and non- 
HDL cholesterol also suggests a unique pathway with the 
context of Africa.
Strengths and weaknesses
A strength of this study is that it compares large, well- 
characterised population studies from one East and one 
Southern African country with comparison studies from 
the UK and include both rural and urban populations. 
The findings of this study are consistent across the African 
studies. Limitations of our study include our African 
studies only representing two countries; however, given 
that highly prevalent low HDL has been reported widely 
in different African populations, it is likely findings may 
be more broadly applicable. A further limitation is that 
there were limited data available to enable exploration of 
factors that might explain these differences; for example, 
most studies did not collect detailed dietary data and one 
study lacked data on alcohol consumption. Given migra-
tion data suggest that genetic differences appear unlikely 
to explain our findings, exploring the potential impact 
of further environmental exposures such as diet, expo-
sure to infection or early undernutrition is an important 
area for future research, alongside assessment of HDL 
functionality and subclass in sub- Saharan African popu-
lations.9 10 43–47 Lastly, participants in the EXTEND study 
were older than those in the other studies; however, the 
results were similar in the EFS and in the age- adjusted 
analysis.
Implications
Our findings raise doubts that low HDL in isolation will 
indicate high cardiovascular risk in the African popula-
tion studied: as those with low HDL have lower non- HDL, 
it is likely they will be at lower rather than higher cardi-
ovascular risk and that the use of prediction tools that 
incorporate HDL developed in other populations may be 
inappropriate.48 Prospective studies that assess the rela-
tionship between lipids and future CVD outcomes in sub- 
Saharan African populations are needed to determine 
the optimal approaches to cardiovascular risk prediction 
in this region. Our results suggest that clinicians should 
not use low HDL in isolation to signify cardiovascular 
risk, until such point as much needed prospective studies 
become available. Our findings also suggest the WHO 
thresholds used internationally for defining low HDL 
may be inappropriate for sub- Saharan African popu-
lations, defining most of the population as low, with a 
marked discrepancy by sex consistent with the loss of sex- 
based variation in HDL in this population. Other defini-
tions relying on HDL (such as metabolic syndrome) will 
therefore also be inappropriate.
CONCLUSIONS
In conclusion, the relationship between HDL, sex and 
cardiovascular risk factors is markedly different in sub- 
Saharan Africa, with low HDL a marker of low overall 
cholesterol, and the large sex differences seen elsewhere 
in the world were not observed. Therefore low HDL is 
unlikely to be a reliable marker of cardiovascular risk in 
this region, and sex- based cut- offs recommended by the 
WHO are unlikely to be appropriate.
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Supplementary table 1: Age and BMI of participants with complete and missing lipid and sex data 
 Malawi (rural) Malawi (urban) Uganda EXTEND  EFS  
 Complete lipids and sex data 
n 10,428 11,180 4,601 7,288 1,458 
Age 
(years) 
34 29 40 56 32 
(25, 47) (22, 37) (27, 54) (43, 66) (29, 35) 
BMI  
(kg/m2) 
22 24 22 26 26 
(22, 23) (24, 24) (22, 22) (26, 26) (25, 26) 
 Missing lipids data 
n 1,586 3,407 25 1,639 100 
Age  
(years) 
33 28 45 52 32 
(24, 52) (22, 36) (36, 72) (41, 65) (29, 36) 
BMI  
(kg/m2) 
22 23 21 26 27 
(22, 22) (23, 23) (19, 22) (26, 26) (26, 28) 
 Missing sex data 
n 0 0 40 0 0 
Age  
(years) 
- - 37 - - 
- - (28, 53) - - 
BMI  
(kg/m2) 
- - 21 - - 
- - (20, 22) - - 
Age is median (IQR) and BMI is geometric mean (95% CI) 
 
 
Supplementary figure 2: Geometric mean HDL for each cohort, adjusted to the median age of the 
participants in the Malawian cohort. 
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Supplementary table 2: Linear regression with HDL as the dependent variable and measures of 
socioeconomic status as independent variables. 
Relationship between socio-economic status and 
HDL 
Men Women 
Malawi (rural): Household possession score 0.00 (-0.00, 0.00) 
p=0.789 
0.00 (-0.00, 0.01) 
p=0.117 
Malawi (urban): Household possession score -0.00 (-0.01, -0.00) 
p=0.039 
0.01 (0.01, 0.01) 
p<0.0001 
Uganda: Socio-economic score 0.00 (-0.01, 0.02) 
p=0.774 
0.03 (0.01, 0.04) 
p<0.0001 
Exeter 10,000: Index of multiple deprivation 0.00 (-0.00, 0.00) 
p=0.475 
0.00 (0.00, 0.00) 
 p=0.001 
Exeter Family Study: Index of multiple 
deprivation 
-0.00 (-0.00, 0.00) 
p=0.163 
-0.00 (-0.01, 0.00) 
p=0.124 
Supplementary table 3: β-coefficients (95% CI) for linear regression analysis of the relationships between HDL and CVD risk 
factors, among men and women in the UK and sub-Saharan Africa. 
 UK Sub-Saharan Africa 
 Men Women Men Women 
n 3,598 5,148 10,701 15,515 
BMI n=3,591 n=5,145 n=10,667 n=15,454 
Unadjusted -0.034 -0.031 -0.007 -0.004 
(-0.037, -0.031) (-0.034, -0.029) (-0.009, -0.005) (-0.005, -0.003) 
Adjusted for age 









(-0.039, -0.033) (-0.036, -0.031) (-0.009, -0.004) (-0.005, -0.003) 
Adjusted for age, 
smoking status and 
alcohol 
consumption 
n=2,645 n-4,638 n=10,667 n=15,454 
-0.038 -0.034 -0.006 -0.004 
(-0.042, -0.034) (-0.036, -0.031) (-0.008, -0.003) (-0.005, -0.003) 
Non-HDL n=3,598 n=5,148 n=10,701 n=15,515 
Unadjusted -0.089 -0.069 0.046 0.041 
Supplementary figure 3: Geometric mean HDL for each cohort, adjusted to the median age of 
the participants in the Malawian cohort, and for smoking status and alcohol consumption. 
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(-0.100, -0.078) (-0.081, -0.057) (0.038, 0.054) (0.036, 0.047) 
Adjusted for age 









(-0.100, -0.077) (-0.128, -0.103) (0.033, 0.049) (0.040, 0.052) 
Adjusted for age, 
smoking status and 
alcohol 
consumption 
n=2,646 n=4,641 n=10,699 n=15,510 
-0.089 -0.116 0.043 0.046 
(-0.103, -0.076) (-0.128, -0.103) (0.035, 0.051) (0.040, 0.052) 
Triglycerides n=3,598 n=5,148 n=10,701 n=15,515 
Unadjusted -0.243 -0.327 -0.075 -0.119 
 (-0.259, -0.227) (-0.350, -0.305) (-0.085, -0.064) (-0.128, -0.109) 
Adjusted for age 
and smoking status 
 






 (-0.101, -0.080) 
-0.148  
(-0.158, -0.137) 
Adjusted for age, 
smoking status and 
alcohol 
consumption 
n=2,646 n=4,641 n=10,699 n=15,510 
-0.269 -0.381 -0.096 -0.149 
(-0.288, -0.250) (-0.404, -0.358) (-0.107, -0.086) (-0.159, -0.138) 
    
Supplementary figure 4: HDL at each level of waist-hip ratio for each cohort. 
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Supplementary figure 7: Spline regression showing HDL at each level of LDL for each cohort, excluding 
participants taking lipid-lowering medication. 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health





Supplementary table 4: β-coefficients (95% CI) for linear regression analysis of the relationships between HDL and CVD risk 
factors, among men and women in the UK and sub-Saharan Africa, excluding individuals who were using lipid lowering medication 
 UK Sub-Saharan Africa 
 Men Women Men Women 
n 3,558 5,107 10,692 15,501 
Non-HDL n=3,209 n=4,806 n=10,692 n=15,501 
Unadjusted -0.904 -0.067 0.046 0.041 









(-0.125, -0.095) (-0.143, -0.116) (0.035, 0.051) (0.040, 0.052) 
Adjusted analyses are adjusted for age, smoking status and alcohol consumption. 
 
Supplementary figure 8: HDL at each level of non-HDL for each cohort, excluding those using lipid 
lowering medication. 
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Supplementary figure 9: Spline regression showing HDL at each level of systolic blood pressure for each cohort 
with available data. 
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